文献速递免疫规划卫生政策与健康促进

基于血液学标准重新评估COVID-19疫苗接种后静脉血栓栓塞风险

Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
PubMed 文献 · Vaccine · 2023-06-07

研究利用英格兰43家国民健康服务信托机构中18-64岁住院患者的血液学结果,重新评估接种ChAdOx1或BNT162b2疫苗后静脉血栓栓塞(VTE)风险。84例接种后VTE病例中12例(14%)符合疫苗诱导免疫性血栓性血小板减少症(VITT)诊断,11例发生于首剂ChAdOx1后、1例发生于首剂BNT162b2后。首剂ChAdOx1后伴血小板减少的脑静脉窦血栓形成(CVT)或其他VTE的归因风险分别为每百万剂2.82和9.62,但不伴血小板减少的VTE风险亦升高。

要点

  • 84例接种后VTE病例中12例(14%)符合VITT诊断,其中11例发生于首剂ChAdOx1后、1例发生于首剂BNT162b2后。
  • 首剂ChAdOx1后伴血小板减少的CVT和其他VTE归因风险分别为每百万剂2.82和9.62。
  • 首剂ChAdOx1后不伴血小板减少的VTE风险亦升高,CVT相对发病率2.67(1.77-3.77),其他VTE为1.93(1.57-2.35)。

核心结论

  • 在接种ChAdOx1疫苗后42天内识别出具有VITT特征的人群,证实了现行诊断标准,同时发现ChAdOx1疫苗接种后不伴血小板减少的VTE风险亦增加。

研究设计与样本

  • 研究纳入英格兰43家国民健康服务信托机构中18-64岁住院患者,获取其血液学结果,诊断确认和血液学参数获取均不知晓疫苗接种状态。
  • 将接种ChAdOx1或BNT162b2 mRNA疫苗后确诊VTE的患者血液学参数与随机选取的40%未接种VTE患者样本进行比较。

主要发现

  • 84例接种后VTE病例中12例(14%)诊断符合VITT,其中11例发生于首剂ChAdOx1后、1例发生于首剂BNT162b2后。
  • 接种组血小板减少(血小板计数<150×10^9/L)17例(20%),未接种组108例中4例(4%)。
  • 全部6例严重血小板减少(<50×10^9/L)均发生于首剂ChAdOx1后42天内。
  • 首剂ChAdOx1后伴血小板减少的CVT和其他VTE归因风险分别为每百万剂2.82和9.62。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An elevated risk of venous thromboembolism (VTE) following a first dose of the ChAdOx1 adenovirus-vectored vaccine was found in a national epidemiological study in England using routine discharge diagnosis codes. Separately, the syndrome of vaccine-induced immune thrombotic thrombocytopenia (VITT) was identified using haematological criteria based on presence of thrombocytopenia, significantly elevated D-dimers and development of anti-PF4 antibodies. To re-evaluate risk estimates using haematological criteria, we obtained the haematology results for hospital admitted patients aged 18-64 years in 43 National Health Service trusts in England who were included in the national epidemiological study. Diagnoses were confirmed and haematological parameters obtained from local records without knowledge of vaccination status. The haematological parameters in patients admitted for a confirmed VTE following ChAdOx1 or BNT162b2 mRNA vaccination were then compared with those in a randomly selected 40% sample of unvaccinated patients with VTE. Overall, 12 (14%) of the 84 vaccinated cases had a diagnosis compatible with VITT, 11 after a first dose of ChAdOx1 and one after a first dose of BNT162b2. Thrombocytopenia (platelet count <150 × 109/L) occurred in 17 vaccinated (20%) and 4 (4%) of 108 unvaccinated patients, with all 6 cases of severe thrombocytopenia (<50 × 109/L) occurring within 42 days of a first dose of ChAdOx1. The attributable risk estimates for a cerebral venous thrombosis (CVT) or other VTE with thrombocytopenia after a first dose of ChAdOx1 vaccine were 2.82 and 9.62 per million doses respectively. However, elevated risks were also found after a first dose of ChAdOx1 for VTE without thrombocytopenia with relative incidences for CVT and other VTE of 2.67 (1.77-3.77) and 1.93 (1.57-2.35) respectively. While we identified a distinct population with features of VITT within 42 days of receiving ChAdOx1 vaccination, confirming current diagnostic criteria, we also found evidence of an increased risk of a VTE without thrombocytopenia after ChAdOx1 vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shaw RJ, Doyle AJ, Millen EA, et al. Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria. Vaccine. 2023. PMID: 37495490. doi:10.1016/j.vaccine.2023.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。